Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Are there studies looking at Ra-223 and SBRT for oligometastatic disease in the setting of mCRPC?
Answer from: Radiation Oncologist at Community Practice
Yes, quite a few including one from UCLA- NCT05496959
Sign In
or
Register
to read more
18046
Related Questions
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
How do you approach radiotherapy planning when there is no identifiable prostate tissue after HIFU or TURP?
With the recent BART, trial how would you manage a positive ureter margin that is now part of the urostomy?
How would you treat a patient with isolated CNS relapse of seminoma?
What is your radiation approach/details for regionally involved prostate cancer (N1)?